{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:45:22Z","timestamp":1793108722042,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:00:00Z","timestamp":1715385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:00:00Z","timestamp":1715385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AstraZeneca","award":["ESR-17-12784"],"award-info":[{"award-number":["ESR-17-12784"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Sodium-glucose co-transporters type 2 inhibitors (SLGT2i) are highly effective in controlling type 2 diabetes, but reported beneficial cardiovascular effects suggest broader actions on insulin resistance. Weight loss may be initially explained by glycosuria-induced net caloric output and secondary volumetric reduction, but its maintenance could be due to loss of visceral fat mass. Structured ultrasound (US) imaging of abdominal adipose tissue (\u201ceco-obesity\u201d) is a recently described methodology used to measure 5 consecutive layers of abdominal fat, not assessable by DEXA or CT scan: superficial subcutaneous (SS), deep subcutaneous (DS), preperitoneal (PP), omental (Om) and right perirenal (RK). PP, Om and RK are predictors of metabolic syndrome (MS) with defined cut-off points. To assess the effect of SLGT2i on every fat depot we enrolled 29 patients with type 2 Diabetes (HbA1c 6.5\u20139%) and Obesity (IMC\u2009&gt;\u200930\u00a0kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ) in an open-label, randomized, phase IV trial (EudraCT: 2019-000979-16): the Omendapa trial. Diabetes was diagnosed\u2009&lt;\u200912\u00a0months before randomization and all patients were treatment na\u00efve. 14 patients were treated with metformin alone (cohort A) and 15 were treated with metformin\u2009+\u2009dapaglifozin (cohort B). Anthropometric measures and laboratory tests for glucose, lipid profile, insulin, HOMA, leptin, ultrasensitive-CRP and microalbuminuria (MAL) were done at baseline, 3rd and 6th months. At 6th month, weight loss was \u22125.5\u2009\u00b1\u20095.2\u00a0kg (5.7% from initial weight) in cohort A and \u22128.4\u2009\u00b1\u20094.4\u00a0kg (8.6%) in cohort B. Abdominal circumference showed a \u22122.7\u2009\u00b1\u20093.1\u00a0cm and \u22125.4\u2009\u00b1\u20092.5\u00a0cm reduction, respectively (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.011). Both Metformin alone (\u221219.4\u2009\u00b1\u200920.1\u00a0mm; \u221221.7%) or combined with Dapaglifozin (\u221220.5\u2009\u00b1\u200919.4\u00a0mm; \u221221.8%) induced significant Om fat reduction. 13.3% of cohort A patients and 21.4% of cohort\u2019s B reached Om thickness below the cut-off for MS criteria. RK fat loss was significantly greater in cohort B group compared to cohort A, at both kidneys. Only in the Met\u2009+\u2009Dapa group, we observed correlations between Om fat with leptin\/CRP\/MAL and RK fat with HOMA-IR. US is a useful clinical tool to assess ectopic fat depots. Both Metformin and Dapaglifozin induce fat loss in layers involved with MS but combined treatment is particularly effective in perirenal fat layer reduction. Perirenal fat should be considered as a potential target for cardiovascular dapaglifozin beneficial effects.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-61590-6","type":"journal-article","created":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T16:16:00Z","timestamp":1715444160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Dapagliflozin added to metformin reduces perirenal fat layer in type 2 diabetic patients with obesity"],"prefix":"10.1038","volume":"14","author":[{"given":"Guillem","family":"Cuatrecasas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"De Cabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Jos\u00e9","family":"Coves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Patrascioiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Cuatrecasas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"March","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Calbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Rossell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariona","family":"Balfeg\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Benito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Di Gregorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Garcia Lorda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,11]]},"reference":[{"issue":"5","key":"61590_CR1","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1210\/jc.2014-3472","volume":"100","author":"A Merovci","year":"2015","unstructured":"Merovci, A. et al. Dapagliflozin lowers plasma glucose concentration and improves \u03b2-cell function. J. Clin. Endocrinol. Metab. 100(5), 1927\u20131932 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"21","key":"61590_CR2","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray, J. J. V. et al. DAPA-HF trial committees and investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381(21), 1995\u20132008 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"61590_CR3","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman, B. et al. EMPA-REG outcome Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373(22), 2117\u201328 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"61590_CR4","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1016\/j.amjcard.2016.08.061","volume":"118","author":"H Tang","year":"2016","unstructured":"Tang, H. et al. Meta-analysis of effects of Sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes and all-cause mortality among patients with type 2 Diabetes mellitus. Am. J. Cardiol. 118(11), 1774\u20131780 (2016).","journal-title":"Am. J. Cardiol."},{"issue":"11","key":"61590_CR5","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.2337\/dc15-2688","volume":"39","author":"G Daniele","year":"2016","unstructured":"Daniele, G. et al. Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 Diabetes. Diabetes Care. 39(11), 2036\u20132041 (2016).","journal-title":"Diabetes Care."},{"issue":"12","key":"61590_CR6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s11892-017-0967-z","volume":"17","author":"MF Gr\u00f8ndahl","year":"2017","unstructured":"Gr\u00f8ndahl, M. F., Keating, D. J., Vilsb\u00f8ll, T. & Knop, F. K. Current therapies that modify glucagon secretion: What is the therapeutic effect of such modifications?. Curr. Diab. Rep. 17(12), 128 (2017).","journal-title":"Curr. Diab. Rep."},{"issue":"12","key":"61590_CR7","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1007\/s00125-016-4097-y","volume":"59","author":"S Casteras","year":"2016","unstructured":"Casteras, S. et al. The suppression of hepatic glucose production improves metabolism and insulin sensitivity in subcutaneous adipose tissue in mice. Diabetologia. 59(12), 2645\u20132653 (2016).","journal-title":"Diabetologia."},{"issue":"420","key":"61590_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.mce.2015.11.019","volume":"15","author":"PJ Millar","year":"2016","unstructured":"Millar, P. J. et al. Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice. Mol. Cell Endocrinol. 15(420), 37\u201345 (2016).","journal-title":"Mol. Cell Endocrinol."},{"issue":"12","key":"61590_CR9","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1517\/13543784.2011.539558","volume":"19","author":"N Katsiki","year":"2010","unstructured":"Katsiki, N., Papanas, N. & Mikhailidis, D. P. Dapagliflozin: More than just another oral glucose-lowering agent?. Expert Opin. Investig. Drugs. 19(12), 1581\u20131589 (2010).","journal-title":"Expert Opin. Investig. Drugs."},{"issue":"3","key":"61590_CR10","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1210\/jc.2011-2260","volume":"97","author":"J Bolinder","year":"2012","unstructured":"Bolinder, J. et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on Metformin. J. Clin. Endocrinol. Metab. 97(3), 1020\u20131031 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"61590_CR11","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/osp4.453","volume":"6","author":"G Cuatrecasas","year":"2020","unstructured":"Cuatrecasas, G. et al. Ultrasound measures of abdominal fat layers correlate with metabolic syndrome features in patients with obesity. Obes. Sci. Pract. 6(6), 660\u2013667 (2020).","journal-title":"Obes. Sci. Pract."},{"issue":"4","key":"61590_CR12","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/jum.14789","volume":"38","author":"AJ Azzi","year":"2019","unstructured":"Azzi, A. J., Lafreni\u00e8re, A. S., Gilardino, M. & Hemmerling, T. US technique in abdominal subcutaneous adipose tissue measurement: a systematic review. J. Ultrasound Med. 38(4), 877\u2013888 (2019).","journal-title":"J. Ultrasound Med."},{"key":"61590_CR13","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/sj.ijo.0801734","volume":"25","author":"RP Stolk","year":"2001","unstructured":"Stolk, R. P. et al. Validity and reproducibility of ultrasonography for the measurement of intra-abdominal adipose tissue. Int. J. Obes. Relat. Metab. Disord. 25, 1346\u20131351 (2001).","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"issue":"1","key":"61590_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cmet.2017.12.002","volume":"27","author":"RK Zwick","year":"2018","unstructured":"Zwick, R. K., Guerrero-Juarez, C. F., Horsley, V. & Plikus, M. V. Anatomical, physiological, and functional diversity of adipose tissue. Cell Metab. 27(1), 68\u201383 (2018).","journal-title":"Cell Metab."},{"issue":"3","key":"61590_CR15","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000443691","volume":"9","author":"I Schlecht","year":"2016","unstructured":"Schlecht, I., Fischer, B., Behrens, G. & Leitzmann, M. F. Relations of visceral and abdominal subcutaneous adipose tissue, body mass index, and waist circumference to serum concentrations of parameters of chronic inflammation. Obes Facts. 9(3), 144\u2013157 (2016).","journal-title":"Obes Facts."},{"issue":"3","key":"61590_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174115","volume":"12","author":"KR Silva","year":"2017","unstructured":"Silva, K. R. et al. Characterization of stromal vascular fraction and adipose stem cells from subcutaneous, preperitoneal and visceral morbidly obese human adipose tissue depots. PLoS One. 12(3), e0174115 (2017).","journal-title":"PLoS One."},{"issue":"10","key":"61590_CR17","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.echo.2015.06.014","volume":"28","author":"A Flynn","year":"2015","unstructured":"Flynn, A. et al. Contrast-enhanced ultrasound: a novel noninvasive, nonionizing method for the detection of brown adipose tissue in humans. J. Am. Soc. Echocardiogr. 28(10), 1247\u20131254 (2015).","journal-title":"J. Am. Soc. Echocardiogr."},{"issue":"3","key":"61590_CR18","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.3892\/ol.2016.4186","volume":"11","author":"A Ciavattini","year":"2016","unstructured":"Ciavattini, A. et al. Thickness of preperitoneal fat as a predictor of malignancy in overweight and obese women with endometrial polyps. Oncol Lett. 11(3), 2278\u20132282 (2016).","journal-title":"Oncol Lett."},{"issue":"3","key":"61590_CR19","first-page":"357","volume":"42","author":"K Fukuda","year":"2015","unstructured":"Fukuda, K. et al. Usefulness of ultrasonographic estimation of preperitoneal and subcutaneous fat thickness in the diagnosis of nonalcoholic fatty liver disease in diabetic patients. J. Med. Ultrasound. 42(3), 357\u2013363 (2015).","journal-title":"J. Med. Ultrasound."},{"issue":"3","key":"61590_CR20","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1089\/aid.2021.0141","volume":"38","author":"A Bonjoch","year":"2022","unstructured":"Bonjoch, A. et al. Ultrasound-based assessment of preperitoneal fat as a surrogate marker of cardiovascular risk: Comparative study between people living with HIV and controls. AIDS Res. Hum. Retroviruses. 38(3), 222\u2013227 (2022).","journal-title":"AIDS Res. Hum. Retroviruses."},{"issue":"5","key":"61590_CR21","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.ultrasmedbio.2013.11.014","volume":"40","author":"B Hacihamdio\u011flu","year":"2014","unstructured":"Hacihamdio\u011flu, B. et al. Preperitoneal fat tissue may be associated with arterial stiffness in obese adolescents. Ultrasound Med. Biol. 40(5), 871\u2013876 (2014).","journal-title":"Ultrasound Med. Biol."},{"issue":"4","key":"61590_CR22","first-page":"411","volume":"90","author":"G Buragina","year":"2019","unstructured":"Buragina, G., Magenta Biasina, A. & Carrafiello, G. Clinical and radiological features of mesenteric panniculitis: A critical overview. Acta Biomed. 90(4), 411\u2013422 (2019).","journal-title":"Acta Biomed."},{"issue":"6","key":"61590_CR23","doi-asserted-by":"publisher","DOI":"10.2196\/11553","volume":"8","author":"M Uittenbogaart","year":"2019","unstructured":"Uittenbogaart, M. et al. Diet-induced alteration of microbiota and development of obesity, nonalcoholic fatty liver disease, and diabetes: study protocol of a prospective study. JMIR Res. Protoc. 8(6), e11553 (2019).","journal-title":"JMIR Res. Protoc."},{"issue":"11","key":"61590_CR24","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.7863\/ultra.32.11.1957","volume":"32","author":"AA Shabestari","year":"2013","unstructured":"Shabestari, A. A., Bahrami-Motlagh, H., Hosseinpanah, F. & Heidari, K. Abdominal fat sonographic measurement compared to anthropometric indices for predicting the presence of coronary artery disease. J. Ultrasound Med. 32(11), 1957\u20131965 (2013).","journal-title":"J. Ultrasound Med."},{"issue":"3","key":"61590_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/jcu.20426","volume":"36","author":"S Kawasaki","year":"2008","unstructured":"Kawasaki, S. et al. Sonographic evaluation of visceral fat by measuring para- and perirenal fat. J. Clin. Ultrasound. 36(3), 129\u2013133 (2008).","journal-title":"J. Clin. Ultrasound."},{"issue":"3","key":"61590_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jchf.2021.12.005","volume":"10","author":"EM Boorsma","year":"2022","unstructured":"Boorsma, E. M., Ter Maaten, J. M., Voors, A. A. & van Veldhuisen, D. J. Renal compression in heart failure: The renal Tamponade hypothesis. JACC Heart Fail. 10(3), 175\u2013183 (2022).","journal-title":"JACC Heart Fail."},{"key":"61590_CR27","doi-asserted-by":"crossref","unstructured":"Cuatrecasas, G., De Cabo, F., Calbo, M., Rossell, O., Dachs, L., Aguilar, G., Coves, M.J., Patrascioiu, I., Benito, C., March, S., Balfeg\u00f3, M., Marina, I., Di Gregorio, S. Effect of liraglutide 3.0 in different abdominal fat layers measured by ultrasound. the importance of perirenal fat. ECO Congress, oral communication 0606, Dublin 18th May (2023).","DOI":"10.1159\/000538996"},{"issue":"861","key":"61590_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172594","volume":"15","author":"JY Zhou","year":"2019","unstructured":"Zhou, J. Y. et al. Liraglutide improves insulin sensitivity in high fat diet induced diabetic mice through multiple pathways. Eur. J. Pharmacol. 15(861), 172594 (2019).","journal-title":"Eur. J. Pharmacol."},{"issue":"9","key":"61590_CR29","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1056\/NEJM199508313330902","volume":"333","author":"RA DeFronzo","year":"1995","unstructured":"DeFronzo, R. A. & Goodman, A. M. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N. Engl. J. Med. 333(9), 541\u2013549 (1995).","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"61590_CR30","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/oby.2012.59","volume":"20","author":"JJ Devenny","year":"2012","unstructured":"Devenny, J. J. et al. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring) 20(8), 1645\u20131652 (2012).","journal-title":"Obesity (Silver Spring)"},{"key":"61590_CR31","unstructured":"Beilby, J. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute\/American Heart Association Conference on Scientific Issues Related to Definition. The Clinical Biochemist Reviews. 25(3), 195\u2013198 (2004)."},{"key":"61590_CR32","first-page":"13","volume":"16","author":"P Gayoso-Diz","year":"2013","unstructured":"Gayoso-Diz, P. et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr. Disord. 16, 13\u201347 (2013).","journal-title":"BMC Endocr. Disord."},{"key":"61590_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/oby.2003.3","volume":"11","author":"W Shen","year":"2003","unstructured":"Shen, W. et al. Adipose tissue Quantification by imaging methods: a proponed classification. Obesity Res. 11, 5\u201316 (2003).","journal-title":"Obesity Res."},{"key":"61590_CR34","first-page":"1","volume":"29","author":"E Park","year":"2009","unstructured":"Park, E., Cho, M. & Ki, C. S. Correct use of repeated measures analysis of variance. Korean J. Lab. Med. 29, 1\u20139 (2009).","journal-title":"Korean J. Lab. Med."},{"issue":"8","key":"61590_CR35","doi-asserted-by":"publisher","first-page":"e4932","DOI":"10.1002\/nbm.4932","volume":"36","author":"B Lavin","year":"2023","unstructured":"Lavin, B. et al. Characterization of hepatic fatty acids using magnetic resonance spectroscopy for the assessment of treatment response to metformin in an eNOS\u2212\/\u2212 mouse model of metabolic nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. NMR Biomed. 36(8), e4932 (2023).","journal-title":"NMR Biomed."},{"issue":"15","key":"61590_CR36","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H. J. L. et al. DAPA-CKD trial committees and investigators. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383(15), 1436\u20131446 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"61590_CR37","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2020.1906","volume":"323","author":"MC Petrie","year":"2020","unstructured":"Petrie, M. C. et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 323(14), 1353\u20131368 (2020).","journal-title":"JAMA."},{"issue":"10","key":"61590_CR38","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1007\/s00261-022-03603-4","volume":"47","author":"M Gjela","year":"2022","unstructured":"Gjela, M., Askeland, A., Fr\u00f8kj\u00e6r, J. B., Mellergaard, M. & Handberg, A. MRI-based quantification of renal fat in obese individuals using different image analysis approaches. Abdom Radiol (NY) 47(10), 3546\u20133553 (2022).","journal-title":"Abdom Radiol (NY)"},{"issue":"4","key":"61590_CR39","doi-asserted-by":"publisher","first-page":"220","DOI":"10.6065\/apem.2019.24.4.220","volume":"24","author":"A L\u00f3pez-Bermejo","year":"2019","unstructured":"L\u00f3pez-Bermejo, A., Prats-Puig, A., Osiniri, I., Mart\u00ednez-Calcerrada, J. M. & Bassols, J. Perirenal and epicardial fat and their association with carotid intima-media thickness in children. Ann. Pediatr. Endocrinol. Metab. 24(4), 220\u2013225 (2019).","journal-title":"Ann. Pediatr. Endocrinol. Metab."},{"issue":"5","key":"61590_CR40","first-page":"564","volume":"10","author":"BN Okeahialam","year":"2020","unstructured":"Okeahialam, B. N., Sirisena, A. I., Ike, E. E. & Chagok, N. M. Ultrasound assessed peri-renal fat: an index of sub-clinical atherosclerosis. Am. J. Cardiovasc. Dis. 10(5), 564\u2013568 (2020).","journal-title":"Am. J. Cardiovasc. Dis."},{"issue":"6","key":"61590_CR41","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41581-019-0145-4","volume":"15","author":"JE Hall","year":"2019","unstructured":"Hall, J. E., Carmo, J. M., da Silva, A. A., Wang, Z. & Hall, M. E. Obesity, kidney dysfunction and hypertension: mechanistic links. Do Nat. Rev. Nephrol. 15(6), 367\u2013385 (2019).","journal-title":"Do Nat. Rev. Nephrol."},{"issue":"3","key":"61590_CR42","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.amjmed.2019.07.041","volume":"133","author":"J N\u00fa\u00f1ez","year":"2020","unstructured":"N\u00fa\u00f1ez, J. et al. CA125-guided diuretic treatment versus usual care in patients with acute heart failure and renal dysfunction. Am J Med. 133(3), 370\u2013380 (2020).","journal-title":"Am J Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-61590-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-61590-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-61590-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T16:16:08Z","timestamp":1715444168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-61590-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,11]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["61590"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-61590-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3504346\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,11]]},"assertion":[{"value":"21 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10832"}}